James Loughlin - Celgene Independent Director
Director
Mr. James J. Loughlin is Independent Director of Celgene Corporationration Mr. Loughlin served as the National Director of the Pharmaceuticals Practice at KPMG LLP, and a fiveyear term as member of the Board of Directors of KPMG. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. Mr. Loughlin serves as a member of the Board of Directors and Chairman of the Audit Committee of Edge Therapeutics, Inc., a publiclytraded biopharmaceutical company since 2007.
| Age | 75 |
| Tenure | 17 years |
| Phone | 908 673-9000 |
| Web | www.celgene.com |
Celgene Management Efficiency
The company has return on total asset (ROA) of 0.14 % which means that it generated a profit of $0.14 on every $100 spent on assets. This is way below average. Celgene's management efficiency ratios could be used to measure how well Celgene manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 20.1 B in liabilities with Debt to Equity (D/E) ratio of 199.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Celgene has a current ratio of 3.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Celgene until it has trouble settling it off, either with new capital or with free cash flow. So, Celgene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celgene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celgene to invest in growth at high rates of return. When we think about Celgene's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mimi Haas | Levi Strauss Co | 67 | |
| James Simmons | Boot Barn Holdings | 60 | |
| Sean Cary | Willamette Valley Vineyards | 40 | |
| Bradley Weston | Boot Barn Holdings | 55 | |
| Travis Knight | Nike Inc | 46 | |
| John Rogers | Nike Inc | 62 | |
| Joshua Prime | Levi Strauss Co | 43 | |
| Cathleen Benko | Nike Inc | 62 | |
| Stanley Turel | Willamette Valley Vineyards | 66 | |
| Peter Henry | Nike Inc | 51 | |
| Brad Brutocao | Boot Barn Holdings | 43 | |
| Brenda Morris | Boot Barn Holdings | 55 | |
| Christopher Sarles | Willamette Valley Vineyards | 49 | |
| Lisa Laube | Boot Barn Holdings | 58 | |
| Christian Johnson | Boot Barn Holdings | 34 | |
| CPA JD | Willamette Valley Vineyards | 77 | |
| Phyllis Wise | Nike Inc | 71 | |
| Tim Cook | Nike Inc | 54 | |
| Jonathan Ricci | Willamette Valley Vineyards | N/A | |
| Jenny Ming | Levi Strauss Co | 65 | |
| Betty OBrien | Willamette Valley Vineyards | 70 | |
Management Performance
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 |
Celgene Leadership Team
Elected by the shareholders, the Celgene's board of directors comprises two types of representatives: Celgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celgene. The board's role is to monitor Celgene's management team and ensure that shareholders' interests are well served. Celgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Loughlin, Independent Director | ||
| Michael Friedman, Independent Director | ||
| Michael Bonney, Director | ||
| Hans Bishop, Director | ||
| John Weiland, Director | ||
| Gerald Masoudi, Executive Vice President General Counsel and Corporate Secretary | ||
| Gilla Kaplan, Independent Director | ||
| Patricia Hall, Director | ||
| Robert Hugin, Chairman of the Board and Presidentident, CEO | ||
| Peter Kellogg, CFO, Executive Vice President | ||
| David Elkins, Executive Vice President | ||
| Perry Karsen, CEO of Celgene Cellular Therapeutics | ||
| Rupert Vessey, President - Research and Early Development | ||
| Carrie Cox, Independent Director | ||
| Terrie Curran, President Global Inflammation & Immunology Franchise | ||
| Michael Pehl, President Hematology & Oncology | ||
| Mark Alles, President, COO and Director | ||
| Alise Reicin, President - Global Clinical Development | ||
| Jonathan Biller, Executive Vice President General Counsel | ||
| Julia Haller, Director | ||
| Robert Hershberg, Chief Scientific Officer | ||
| Jacqualyn Fouse, President of Global Hematology and Oncology and Director | ||
| Ernest Mario, Independent Director | ||
| Scott Smith, President - Inflammation & Immunology | ||
| Thomas Daniel, Executive Vice President and Presidentident - Research and Early Development | ||
| Richard Barker, Independent Director | ||
| Michael Casey, Lead Independent Director |
Celgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 51.47 % | |||
| Current Valuation | 85.34 B | |||
| Shares Outstanding | 708.74 M | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 77.62 % | |||
| Number Of Shares Shorted | 12.95 M | |||
| Price To Earning | 13.31 X |
Pair Trading with Celgene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celgene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celgene will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |